Is CJC-1295 legal? the comprehensive answer. | Reddit

Current US FDA status

CJC-1295 is not an FDA-approved drug. There is no completed New Drug Application, no approved label, no agency-approved indication, and no finished pharmaceutical product to dispense. The ConjuChem development program reached Phase 2 trials in HIV-associated lipodystrophy and was discontinued without registration.

Beyond drug approval, the question that matters for access is whether licensed compounding pharmacies can prepare CJC-1295 from bulk drug substance. That question is governed by the FDA’s bulk drug substance category lists. Three categories matter:

• Category 1: Bulk drug substances under evaluation. FDA’s interim policy extends enforcement discretion to 503A compounding with these substances when its conditions are met.
• Category 2: Bulk drug substances that raise significant safety risks.
• Category 3: Bulk drug substances nominated without adequate support.

CJC-1295 was nominated for the 503A Bulks List, and on September 29, 2023 FDA added it to Category 2 of its interim policy. FDA cited immunogenicity risk, peptide-related impurities and API characterization, and serious adverse events including increased heart rate and systemic vasodilatory reaction.

On September 27, 2024, FDA removed CJC-1295 from Category 2 because the nominations were withdrawn by the nominators, and said it would still consult PCAC. FDA now lists it among nominations withdrawn. It is not in Category 1 and not on the 503A Bulks List. The Pharmacy Compounding Advisory Committee (PCAC) reviewed it on December 4, 2024 and voted against all five CJC-1295 forms, as FDA had proposed. The April 15, 2026 changes moved other peptides, such as BPC-157 and TB-500, out of Category 2 and did not change CJC-1295’s status.

How CJC-1295 ended up where it did

The trajectory explains how CJC-1295 reached its current status.

1. 2004 to 2006: ConjuChem develops CJC-1295 with DAC and runs the Phase 1 trial published by Teichman and colleagues in 2006. The trial demonstrates sustained GH and IGF-1 elevation for roughly a week from a single subcutaneous dose.
2. Late 2000s: ConjuChem advances CJC-1295 into Phase 2 trials for HIV-associated lipodystrophy. The rationale parallels tesamorelin, a separately developed GHRH analog that would receive FDA approval for that indication in 2010.
3. Early 2010s: ConjuChem winds down. The CJC-1295 development program does not pass to a successor sponsor that pursues a registrational program. The compound’s pharmaceutical-development trajectory effectively ends.
4. Mid 2010s onward: CJC-1295 appears as a research chemical sold by overseas vendors, then as a compounded peptide offered by a subset of US compounding pharmacies under the assumption that it could be prepared from bulk drug substance.
5. September 29, 2023: FDA adds CJC-1295 to 503A Category 2, citing immunogenicity risk, peptide-related impurities and API characterization, and serious adverse events including increased heart rate and systemic vasodilatory reaction.
6. September 27, 2024: FDA removes CJC-1295 from Category 2 because the nominations were withdrawn by the nominators, and says it will still consult PCAC.
7. December 4, 2024: FDA proposes against including CJC-1295 on the 503A Bulks List, and PCAC votes against all five forms (13 to 0 on four forms and 12 to 1 on CJC-1295 acetate).

The molecule has more peer-reviewed Phase 1 data than most compounded peptides, because the Teichman 2006 trial was published in a major endocrinology journal. That data did not carry it onto the Bulks List: FDA proposed against inclusion and PCAC agreed. The development program also stopped short of pivotal trials, and the DAC and non-DAC forms are both sold under the same name.

The compounding implication: what Category 2 meant

One detail that needs to be precise: Category 2 is FDA’s list of bulk substances that raise significant safety risks, and CJC-1295 sat on it from September 29, 2023 to September 27, 2024. Every PepScribe prescription is filled by a licensed 503A pharmacy, and that standard holds regardless of clinician interest, patient demand, or claimed pharmacy expertise. The Category 2 designation, while it was in effect, was a hard stop.

CJC-1295 is no longer in 503A Category 2. It is not on the 503A Bulks List or in Category 1, and FDA’s interim policy extends enforcement discretion only to Category 1 substances. PCAC voted against Bulks List placement in 2024.

PepScribe routes questions about GHRH-axis therapy to a clinician consultation, where a licensed clinician reviews your history and the options that fit it. This reflects CJC-1295’s regulatory status and says nothing about whether the molecule is pharmacologically interesting.

Gray-market risks: purity, sterility, dosing accuracy

Vials labeled “CJC-1295” are widely available from research chemical suppliers, overseas pharmacies, and underground markets. The risks of these sources are not theoretical. They are the same risks that show up across the gray-market peptide landscape, with one additional layer that CJC-1295 introduces.

Purity and identity

Without pharmaceutical-grade manufacturing oversight, products sold as CJC-1295 may contain truncated peptide chains, partially synthesized sequences, the wrong variant entirely, or a different peptide altogether. Independent third-party testing of gray-market peptide samples has repeatedly found mislabeled or substandard products across the broader peptide market. CJC-1295 is not exempt from this pattern.

The dual-form issue (DAC vs non-DAC) compounds the identity problem. Vials sometimes mix up which variant is in the bottle, particularly when sourced through informal channels. The DAC and non-DAC forms have very different pharmacokinetic profiles, and a patient expecting non-DAC short-acting pharmacology who receives DAC long-acting pharmacology will experience continuous receptor stimulation for days when they expected hours. The dosing implications are not minor.

Sterility

Injectable peptides require strict sterility controls. Bacterial endotoxins are particularly problematic because they survive sterilization steps that kill bacteria themselves. Gray-market vials lack the validated sterility processes that licensed pharmaceutical and 503A compounding facilities operate under. The risk of injection-site infection, abscess, or systemic infection from non-sterile preparations is real and well-documented across the gray-market peptide world.

Dosing accuracy, with a CJC-1295-specific twist

Gray-market vials are often labeled by mass (for example, “5 mg per vial”) but the actual peptide content can deviate substantially from the label claim, in either direction. Underfilling means an underdose; overfilling means an overdose. For most peptides this is bad enough.

For CJC-1295 with DAC specifically, the consequences of a wrong dose persist for days, not hours. A non-DAC peptide that you mis-dosed at 3 PM clears by bedtime; you got an unintentional acute exposure and the system recovers overnight. A DAC peptide that you mis-dosed at 3 PM is still in your system a week later, with sustained GH and IGF-1 elevation, with no easy way to speed clearance, and with whatever endocrine consequences follow from a week-long unintended dose. The long half-life that makes CJC-1295 with DAC attractive from an adherence perspective also makes dosing errors much more consequential.

This is one of the strongest arguments against gray-market sourcing for the DAC variant in particular. The margin for error is much smaller, the consequences last much longer, and the ability to reverse course is effectively zero.

The “research use only” legal disclaimer

Most gray-market peptide vendors label their products “for research use only” or “not for human consumption.” This is a legal disclaimer that allows the vendor to sell substances outside the pharmaceutical regulatory framework. It does not create a legitimate self-administration pathway, it does not protect the buyer, and it does not imply that the product meets any quality standard. It is a litigation shield, not a quality assurance.

International picture: UK, Canada, Australia, EU

CJC-1295 has never received marketing approval in any major regulatory jurisdiction. The picture across the most-asked-about countries:

United Kingdom

The Medicines and Healthcare products Regulatory Agency (MHRA) has not approved CJC-1295 as a medicine. It cannot be legally sold as a medicine or health product in the UK. Research chemical sourcing sits outside that framework, much like the US gray market, but UK compounding regulations do not provide a 503A-equivalent pathway for unapproved peptides.

Canada

Health Canada has not approved CJC-1295 as a drug, and it does not appear in the Drug Product Database or the Licensed Natural Health Products Database. Canadian compounding pharmacies operate under provincial regulations, and preparation of unapproved peptides is generally more restricted than under US 503A rules. Personal-use importation from international sources may violate the Food and Drugs Act, particularly when the substance is represented as therapeutic.

Australia

The Therapeutic Goods Administration (TGA) takes a notably strict approach to peptides. CJC-1295 is not on the Australian Register of Therapeutic Goods (ARTG). The TGA has specifically targeted unapproved peptide importation and sale, and Australian Border Force has seized peptide shipments at the border. Compounding pharmacies in Australia operate under state and territory regulations and generally cannot prepare substances that are not TGA-approved without specific exemptions. Australia’s regulatory environment is among the most restrictive globally for peptide access.

European Union

The European Medicines Agency (EMA) has not approved CJC-1295. Tesamorelin, a structurally related GHRH analog, has FDA approval for HIV-associated lipodystrophy in the United States, but its EMA application for the same indication was withdrawn before approval. CJC-1295 itself does not have approval anywhere in the EU, and individual member states’ rules on compounding and personal-use importation vary, with most operating closer to the Australian model than the US 503A model.

International takeaway

No major regulatory jurisdiction has approved CJC-1295 for therapeutic use. The US 503A compounding-pharmacy framework has no close equivalent in most other countries. If you are researching CJC-1295 from outside the United States, the practical reality is that legal therapeutic access is essentially closed, and gray-market sourcing carries the standard purity, sterility, and identity risks plus customs and importation exposure.

WADA prohibition: CJC-1295 is banned in competitive sport

CJC-1295 is prohibited by the World Anti-Doping Agency under Section S2 of the Prohibited List, which covers peptide hormones, growth factors, related substances, and mimetics. CJC-1295 is named explicitly under S2.2.4, the Growth Hormone Releasing Factors subcategory, alongside other GHRH analogs including sermorelin and tesamorelin. Athletes subject to WADA jurisdiction cannot use it.

Key points for athletes at any level:

• The ban applies in-competition and out-of-competition. There is no off-season exception for peptide hormones and growth factors.
• Therapeutic Use Exemption is essentially unavailable. Because CJC-1295 has no approved therapeutic indication anywhere in the world, a Therapeutic Use Exemption application would have nothing to point to. Tesamorelin (FDA-approved for HIV lipodystrophy) is the only GHRH-analog drug class member with an approved indication, and even that is narrowly scoped.
• Detection methods exist. Anti-doping laboratories have developed and continue to refine detection methods for synthetic GH-secretagogues. The long half-life of the DAC form, in particular, leaves a longer detection window than short-acting GH-axis agents.
• Sanctions are severe. A positive test for a WADA-prohibited substance can result in multi-year competition bans, loss of titles and medals, financial penalties, and reputational damage that does not fade.
• The prohibition extends beyond elite sport. Many collegiate, amateur, and professional sports organizations adopt the WADA Prohibited List or maintain parallel lists that include CJC-1295.

If you are a competitive athlete at any level, consult the current WADA Prohibited List directly (wada-ama.org/en/prohibited-list) and your sport’s anti-doping authority before considering any GH-axis peptide.

Possession vs sale: a useful legal distinction

Patients often conflate three different questions: can I be arrested for having this, can someone be arrested for selling this, and can I get a doctor to prescribe this through a regulated pharmacy? They are not the same questions, and they do not have the same answers.

• Possession in the United States: CJC-1295 is not on any schedule of the Controlled Substances Act. Simple possession of CJC-1295 is unlikely to result in criminal charges in most US contexts, although this depends on jurisdiction and surrounding facts. This is not the same as “legal” in any practical sense.
• Sale in the United States: Selling CJC-1295 as a finished pharmaceutical product without FDA approval, or marketing it as a dietary supplement, both fall outside the regulatory framework. The FDA has taken enforcement action against vendors selling peptides with research-use disclaimers when the marketing context indicated intent for human consumption.
• Compounding in the United States: CJC-1295 is not on the 503A Bulks List and not in Category 1, and FDA’s interim policy extends enforcement discretion only to Category 1 substances. PCAC voted against all five CJC-1295 forms on December 4, 2024.
• Personal importation: US personal-use importation of unapproved drugs operates under FDA enforcement discretion, which is narrower than many online vendors imply. Customs seizure of peptide shipments is a real and recurring outcome.

The practical answer is that “legal” for CJC-1295 means different things at different levels of the supply chain. The clearest next step for anyone interested in GHRH-axis therapy is a licensed clinician, who can review your history and the options that fit it.

What reclassification would require

Placing CJC-1295 on the 503A Bulks List would require FDA to evaluate the molecule again against the criteria the agency uses for the list. Those criteria typically include:

• Identity and characterization: The substance must be well-characterized chemically, with reference standards available, and methods established for verifying identity in bulk drug substance. The DAC vs non-DAC distinction complicates this because the bulk-drug-substance form needs to be specified.
• Safety data: Sufficient safety information to support compounding for the intended use, which for CJC-1295 is currently limited to the Phase 1 record plus extrapolation from related GHRH-analog drugs.
• PCAC review: The Pharmacy Compounding Advisory Committee provides a formal recommendation to FDA on whether a substance should be placed on the 503A Bulks List.
• Federal Register publication: Any final classification decision is published in the Federal Register, which is the official journal of the US federal government and the formal vehicle for regulatory action.

The December 4, 2024 PCAC review went against all five CJC-1295 forms, as FDA had proposed. Reaching the Bulks List would take a new evaluation, a new PCAC recommendation, and Federal Register publication. CJC-1295 is outside Category 1 and off the Bulks List.

For patients, the practical advice is to work with clinicians and pharmacies that follow FDA’s current lists and watch for any new FDA action. PepScribe handles GHRH-axis questions consultation-first: a licensed clinician reviews your history and discusses the options that fit it.

Options in the same drug class to discuss with a clinician

For patients exploring GHRH-axis support who want to work within a clean regulatory state, sermorelin is the clinician-prescribed path. Sermorelin is the unmodified GHRH(1-29) parent compound, the molecule that CJC-1295 was engineered from. It is a clinician-prescribed peptide on PepScribe’s commercial roster. It was the active ingredient in Geref, an FDA-approved drug discontinued in 2008 for reasons FDA determined in 2013 were not safety or effectiveness; licensed 503A pharmacies compound it by prescription.

The reasons sermorelin works as a sermorelin-for-CJC-1295 substitute:

• Same receptor target: Sermorelin and CJC-1295 both bind the pituitary GHRH receptor and trigger the same downstream signaling cascade. The mechanism is the same; the engineering around half-life is what differs.
• Established clinical record: Sermorelin was the active ingredient in Geref, an FDA-approved drug discontinued in 2008 for reasons FDA determined in 2013 were not safety or effectiveness, and that clinical history informs current dosing and monitoring practice.
• Pulsatile pharmacokinetics: Sermorelin’s short half-life produces discrete GH pulses that mimic physiological GHRH release, which some clinicians regard as the preferable receptor-exposure pattern.
• Compounded by prescription: Licensed 503A pharmacies compound sermorelin against a clinician’s prescription, with the same accountability as for any compounded medication.
• Available commercially: PepScribe offers sermorelin as a clinician-prescribed product. A licensed clinician evaluates the patient, prescribes if appropriate, and a 503A pharmacy fills the prescription.

Sermorelin is not a perfect drop-in for every patient considering CJC-1295. The pharmacokinetic profiles are different, sermorelin requires more frequent dosing, and the convenience advantage of the once-weekly DAC form is real. But for most GH-axis goals in healthy adults working within a clinician-supervised framework, sermorelin offers the combination of a well-characterized mechanism, a clean regulatory state, a licensed 503A supply chain, and a real safety record that CJC-1295 currently does not.

If you are evaluating GHRH-axis support and CJC-1295’s regulatory status is part of why you ended up on this page, sermorelin is the answer to that question. It is the same drug class, the same receptor mechanism, the same family of clinical applications, and an entirely different regulatory state.

Summary table: where CJC-1295 stands

No major jurisdiction offers a clean route to CJC-1295. In the United States, it is not FDA-approved, not on the 503A Bulks List, outside 503A Category 2 since its nominations were withdrawn, and outside Category 1, the only category FDA’s interim enforcement discretion covers. In every other major jurisdiction, the answer is closer to no clean access at all. WADA prohibits it for competitive sport globally.

For now, the practical course is to watch for any new FDA action, consult licensed healthcare providers, and consider whether the established alternative, sermorelin, addresses the underlying clinical goal that brought you to CJC-1295 in the first place.